US20140018391A1 - Methods of Producing Anamorelin Hydrochloride Having Controlled Chloride Content - Google Patents
Methods of Producing Anamorelin Hydrochloride Having Controlled Chloride Content Download PDFInfo
- Publication number
- US20140018391A1 US20140018391A1 US13/865,649 US201313865649A US2014018391A1 US 20140018391 A1 US20140018391 A1 US 20140018391A1 US 201313865649 A US201313865649 A US 201313865649A US 2014018391 A1 US2014018391 A1 US 2014018391A1
- Authority
- US
- United States
- Prior art keywords
- anamorelin
- anamorelin monohydrochloride
- monohydrochloride
- composition
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- QTIAVBREUMLDNZ-WXGMZPBLSA-N CN(C)N(C)C(=O)[C@@]1(CC2=CC=CC=C2)CCCN(C(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(C)(C)C)C1 Chemical compound CN(C)N(C)C(=O)[C@@]1(CC2=CC=CC=C2)CCCN(C(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(C)(C)C)C1 QTIAVBREUMLDNZ-WXGMZPBLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to anamorelin hydrochloride, improved forms of anamorelin hydrochloride having reduced impurities and controlled chloride content, and improved processes for making and using anamorelin hydrochloride.
- Growth hormone is a major participant in the control of several complex physiologic processes including growth and metabolism. Growth hormone is known to have a number of effects on metabolic processes such as stimulating protein synthesis and mobilizing free fatty acids, and causing a switch in energy metabolism from carbohydrate to fatty acid metabolism. Deficiencies in growth hormone can result in dwarfism and other severe medical disorders.
- growth hormone release can be stimulated by growth hormone releasing hormone (GHRH) and inhibited by somatostatin.
- GHRH growth hormone releasing hormone
- Anamorelin is one such compound.
- Anamorelin is a synthetic orally active compound originally synthesized in the 1990s as a growth hormone secretagogue for the treatment of cancer related cachexia.
- the free base of anamorelin is chemically defined as:
- 6,576,648 also yields a final product that contains more than 5000 ppm (0.5%) of residual solvents, which renders the product less desirable from a pharmaceutical standpoint, as described in ICH Harmonized Tripartite Guideline. See Impurities: Guideline for residual solvents Q3C(R3).
- anamorelin free base in the organic phase is protonated by the hydrochloric acid it migrates into the aqueous phase.
- the controlled ratio of anamorelin free base and hydrochloric acid and homogenous distribution in the aqueous phase allows for the controlled formation of the monohydrochloride salt over the dihydrochloride, and the controlled distribution of the resulting chloride levels within individual batches and among multiple batches of anamorelin monohydrochloride.
- the invention provides methods for preparing anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride comprising: (a) dissolving anamorelin free base in an organic solvent to form a solution; (b) mixing said solution with water and hydrochloric acid for a time sufficient to: (i) react said anamorelin free base with said hydrochloric acid, and (ii) form an organic phase and an aqueous phase; (c) separating the aqueous phase from the organic phase; and (d) isolating anamorelin monohydrochloride from the aqueous phase.
- the molar ratio of anamorelin to hydrochloric acid used in the process is less than or equal to 1:1, so as to reduce the production of anamorelin dihydrochloride and other unwanted chemical species.
- hydrochloric acid can be added at a molar ratio of from 0.90 to 1.0 relative to said anamorelin, from 0.90 to 0.99, or from 0.93 to 0.97.
- the anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride is isolated from the aqueous phase via spray drying, preferably preceded by distillation.
- This technique has proven especially useful in the manufacture of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride because of the excellent reduction in solvent levels observed, and the production of a stable amorphous form of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride.
- the invention relates to the various forms of anamorelin monohydrochloride and compositions comprising anamorelin monohydrochloride produced by the methods of the present invention.
- the invention provides anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having an inter-batch chloride content of from 5.8 to 6.2%, preferably from 5.8 to less than 6.2%.
- the invention provides anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having a molar ratio of chloride to anamorelin less than or equal to 1:1, such as from 0.9 to 1.0 or 0.99.
- the invention provides an amorphous form of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride. Further descriptions of the anamorelin monohydrochloride and compositions comprising the anamorelin monohydrochloride are given in the detailed description which follows.
- the present invention relates to:
- Anamorelin monohydrochloride comprising a chloride:anamorelin molar ratio of from 0.9 to 0.99.
- composition comprising anamorelin monohydrochloride, wherein the composition comprises a chloride content of from 5.8 to 6.2%.
- composition comprising anamorelin monohydrochloride wherein the composition comprises a chloride:anamorelin molar ratio of from 0.9 to 0.99.
- Par. 20 The composition of Par. 19, comprising a residual solvent selected from methanol, butyl acetate, propyl acetate, ethyl acetate, isopropyl acetate, isobutyl acetate, methyl acetate, methylethyl ketone, methylisobutyl ketone, 2-methyltetrahydrofuran and combinations thereof in an amount less than 1000 ppm.
- a residual solvent selected from methanol, butyl acetate, propyl acetate, ethyl acetate, isopropyl acetate, isobutyl acetate, methyl acetate, methylethyl ketone, methylisobutyl ketone, 2-methyltetrahydrofuran and combinations thereof in an amount less than 1000 ppm.
- composition comprising anamorelin monohydrochloride in the substantial absence of anamorelin hydrochloride other than anamorelin monohydrochloride, having a chloride content of from 5.8 to 6.2%, less than 0.5% residual solvent, and a purity greater than 99%.
- a pharmaceutical composition comprising:
- a method of making a pharmaceutical dosage form comprising:
- FIG. 1 is an X-ray powder diffraction pattern of amorphous anamorelin monohydrochloride or a composition comprising amorphous anamorelin monohydrochloride prepared according to the methods of the present invention.
- FIG. 2 is an infrared spectrum in KBr of amorphous anamorelin monohydrochloride or a composition comprising amorphous anamorelin monohydrochloride prepared according to the methods of the present invention.
- “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
- Impurity refers to any chemical in a pharmaceutical ingredient other than anamorelin monohydrochloride as the ingredient itself and water. Impurities thus include reaction by-products, contaminants, degradation products, and residual solvents such as organic volatile impurities.
- Residual solvent refers to any organic solvent which is used in preparing anamorelin monohydrochloride.
- isolated refers to a state suitable for use as an active pharmaceutical ingredient in solid form, prior to admixing with any pharmaceutically acceptable excipients.
- the term generally requires that the recited ingredient be present as an isolated solid material to the exclusion of any pharmaceutically acceptable excipients, and preferably having less than 10, 5, 3, 1, or 0.5% impurities.
- “Anamorelin monohydrochloride” refers to the salt form of anamorelin comprising a precise 1:1 stoichiometric ratio of anamorelin and HCl (i.e. 6.08 wt % Cl—).
- the anamorelin monohydrochloride may be present within a composition that does not have a precise 1:1 ratio of anamorelin and HCl because, for example, the composition may contain small quantities of anamorelin free base and/or anamorelin hydrochloride (e.g., anamorelin dihydrochloride) other than anamorelin monohydrochloride which do not substantially affect the stability of the composition.
- anamorelin monohydrochloride or “a composition comprising anamorelin monohydrochloride” may comprise from 5.6 to 6.3 wt %, and preferably from 5.8 to 6.2 wt %, more preferably from 5.9 or 6.0 to 6.1 wt % chloride.
- the chloride content in the composition is calculated by the formula described in the Example 1.
- the “hydrochloride” salt of anamorelin in contrast, encompasses any molar ratio of anamorelin to HCl.
- “Anamorelin” is used herein to refer to the hydrochloride salt of anamorelin as well as the free base, and should not be taken to mean the free base unless stated so expressly.
- a composition comprising anamorelin monohydrochloride refers to the active pharmaceutical ingredient which comprises anamorelin monohydrochloride and does not include any pharmaceutically acceptable excipients. More concretely the term refers to the composition having a chloride content ranging from 5.8 to 6.2%, preferably from 5.8 to 6.1%, in the substantial absence of anamorelin free base, anamorelin hydrochloride other than anamorelin monohydrochloride, and without any pharmaceutically acceptable excipients.
- “Purity” refers to the converted value into anamorelin free base within the sample when anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride prepared by the methods of present invention is measured via HPLC under the conditions described in Example 3.
- anamorelin hydrochloride of the present invention provides methods of producing high-quality anamorelin monohydrochloride as an active pharmaceutical ingredient, as well as the product produced by such methods.
- the anamorelin hydrochloride of the present invention is preferably referred to simply as anamorelin hydrochloride, but could also be considered a composition comprising anamorelin monohydrochloride, due to the presence of impurities and degradation products.
- the present invention provides methods for preparing anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having a controlled content and distribution of chloride comprising: (a) dissolving anamorelin free base in an organic solvent to form a solution; (b) mixing said solution with water and hydrochloric acid for a time sufficient to: (i) react said anamorelin free base with said hydrochloric acid; and (ii) form an organic phase and an aqueous phase; (c) separating the aqueous phase from the organic phase; and (d) isolating anamorelin monohydrochloride from the aqueous phase.
- the organic solvent used to prepare the initial solution is preferably one in which (i) anamorelin free base is more soluble than it is in water (ii) anamorelin monohydrochloride is less soluble than it is in water, (iii) the organic solvent has limited miscibility with water, and (iv) the organic solvent forms an azeotrope with water or has a lower boiling point than water.
- Suitable organic solvents for the anamorelin free base include but are not limited to butyl acetate, propyl acetate, ethyl acetate, isopropyl acetate, isobutyl acetate, methyl acetate, methylethyl ketone, methylisobutyl ketone and 2-methyltetrahydrofuran, preferably isopropyl acetate.
- the concentration of the hydrochloric acid solution is governed primarily by the desired molar ratio of anamorelin and chloride in the final composition, which will dictate the number of moles of hydrochloric acid in the aqueous phase.
- the molarity of the hydrochloric acid solution ranges from about 0.1 to about 13 or from about 1.0 to about 10, and the volume of the solution is determined by the molarity of the solution and the quantity of anamorelin to be reacted.
- the molar ratio of chloride to anamorelin free base in the reaction vessel can range from about 0.85 to about 1.04, from about 0.92 to about 1.02, from about 0.92 to about 1.00, or from about 0.93 to about 0.97.
- the organic phase can be separated from the aqueous phase by any suitable phase extraction technique, including physical extraction of one phase from the mixture or distillation. Distillation can be performed using various means, such as simple distillation, fractional distillation, vacuum distillation and preferably azeotropic distillation. The distillation temperature is determined based upon the boiling point of the particular organic solvent(s) intended to be removed.
- the anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride can be isolated from the aqueous phase via known techniques, including settling, sedimentation and concentration. Concentration is the preferred method, particularly concentration via spray drying, optionally in the presence of an inert gas.
- Spray drying is a method of producing a dry powder from a liquid or slurry by rapidly drying with a hot gas. It is well suited for the continuous production of dry solids in either powder, granulate or agglomerate form from liquid feedstocks as solutions, emulsions and pumpable suspensions. Spray drying is an ideal process where the end-product must comply with precise quality standards regarding particle size distribution, residual moisture content, bulk density, and/or particle shape.
- Spray drying involves the atomization of a liquid feedstock into a droplet spray, and contacting the droplets with hot air in a drying chamber.
- the spray is produced by either a rotary (wheel) or nozzle atomizer. Evaporation of moisture from the droplets and formation of dry particles proceed under controlled temperature and airflow conditions. Powder is discharged continuously from the drying chamber. Operating conditions and dryer design are selected according to the drying characteristics of the product and powder specifications.
- a spray dryer is a device used in spray drying. It takes a liquid stream and separates the solute or suspension from a liquid phase by evaporating the solvent. The solid is usually collected in a drum or cyclone. The liquid input stream is sprayed through a nozzle into a hot vapor stream and vaporized. Solids form as moisture quickly leaves the droplets. A nozzle is usually used to make the droplets as small as possible, maximizing heat transfer and the rate of water vaporization.
- a representative spray dryer comprises a feed pump, atomizer, air heater, air disperser, drying chamber, and systems for exhaust air cleaning and powder recovery. The selection of the atomizer, the most suitable airflow pattern, and the drying chamber design are determined by the drying characteristics and quality requirements for the particular product.
- spray dryers can be used in the spray drying step according to the present invention.
- a representative example is the Mini-Spray Dryer (Model: Buchi 190, Switzerland), which operates in a co-current manner, i.e., the sprayed product and the drying gas flow in the same direction.
- Other suitable spray dryers include the Niro Mobile Minor (trade mark, GEA Process Engineering Inc.), Niro QSD-3.6 (trade mark, GEA Process Engineering Inc.), L-8i (Ohkawara Kakoki Co., Ltd.) and so forth.
- the drying gas can be air or inert gases such as nitrogen, argon and carbon dioxide.
- the spray drying is preferably carried out with the inlet gas temperature in the range of from about 180 to about 200° C. and the outlet gas temperature in the range of from about 80 to about 100° C. Preferred methods of spray drying the anamorelin hydrochloride are given in the examples hereto.
- Still other embodiments pertain to the novel forms of anamorelin monohydrochloride or compositions comprising anamorelin monohydrochloride produced by the present invention.
- the invention provides for anamorelin monohydrochloride or compositions comprising anamorelin monohydrochloride having a uniformly controlled chloride content among batches.
- the invention provides anamorelin monohydrochloride having an inter-batch (i.e. batch-to-batch) chloride content that varies by no more than 7%, 5%, 3% or even 2%.
- the invention may provide anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having an inter-batch chloride content that ranges from 5.8 to 6.2%, 5.9 to 6.2%, 5.9 to 6.1%, or 6.0 to 6.1%.
- the invention provides anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having a molar ratio of chloride to anamorelin of from 0.92 to 1.02, or from 0.95 to 1.00. This ratio can exist throughout an entire batch, as an average of samples taken from the batch, or as one or more samples within a batch.
- a third principal embodiment provides anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride in an amorphous state.
- the amorphous state can be represented by an X-ray powder diffraction pattern substantially as depicted in FIG. 1 or, alternatively or in addition, by the infrared resonance spectrum depicted in FIG. 2 .
- the anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride of each of the foregoing principal embodiments is preferably highly soluble in water.
- the solubility in water of the anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride is preferably greater than about 100 mg/ml.
- the anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride also preferably has a low residual solvent content.
- the total organic volatile impurities such as methanol, isopropanol, isopropyl acetate, ethyl acetate or other organic solvents used in preparing the drug substance are preferably less than 5,000 ppm, 3,000 ppm, or even 1,000 ppm.
- the anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride has a residual solvent content less than about 0.5%, 0.3%, or even 0.1% based upon the total weight of the anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride.
- the anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride of each of the foregoing embodiments preferably has high purity and low impurities including residual solvents.
- total impurities such as by-products, contaminants, degradation products and residual solvents used in preparing the drug substance are preferably less than 3%, 2%, 1%, or 0.5%.
- the anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride is in a pharmaceutically acceptable form having greater than 97%, 98%, or even 99% purity.
- the anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride of each of the foregoing embodiments can be characterized by the weight percent of chloride in the composition, or in a sample of the composition, and in various embodiments the anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride is defined by a chloride content ranging from about 5.8% to about 6.2%, and preferably from about 5.9% to about 6.1% (or 6.08%).
- the anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride can also be characterized by its water content, alternatively or in addition to the other characteristics of the compound, and in various embodiments the compounds of the present invention comprise less than 5, 4, 3 or 2% water.
- anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride of the present invention has growth hormone secretagogue activity, it is useful for preventing and/or treating conditions which require increased plasma growth hormone levels, as in growth hormone deficient humans, elderly patients and livestock.
- the anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride is found particularly useful in the treatment of cancer related cachexia.
- the anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride of the present invention can be present in an isolated state or, alternatively, it can be formulated into a pharmaceutical dosage form (i.e., pharmaceutical composition) that comprises a therapeutically effective amount of the compound and one or more pharmaceutically acceptable excipients.
- pharmaceutical dosage form i.e., pharmaceutical composition
- pharmaceutically acceptable excipient includes solvents, dispersion media, coatings, antibacterial and antifungal agents, tonicity agents, buffers, antioxidants, preservatives, absorption delaying agents, and the like, compatible with pharmaceutical administration.
- compositions can be included in a container, pack, or dispenser together with instructions for administration.
- a pharmaceutical composition is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, oral, transmucosal, and rectal administration.
- the compounds for use in the method of the invention can be formulated for administration by any suitable route, such as for oral or parenteral, for example, transmucosal (e.g., sublingual, lingual, (trans)buccal, nasal, (trans)dermal, and (trans)rectal) administration.
- compositions and dosage forms include tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, gels, powders, pellets, magmas, lozenges, discs, suppositories, liquid sprays, or dry powders.
- anamorelin monohydrochloride or the composition comprising anamorelin monohydrochloride be orally administered.
- suitable oral dosage forms include, for example, tablets, capsules or caplets prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., polyvinylpyrrolidone or hydroxypropylmethylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., sodium starch glycolate); and/or wetting agents (e.g., sodium lauryl sulfate).
- binding agents e.g., polyvinylpyrrolidone or hydroxypropylmethylcellulose
- fillers e.g., lactose, microcrystalline cellulose or calcium phosphate
- lubricants e.g., magnesium stearate, talc or silica
- disintegrants
- the tablets can be coated, e.g., to provide for ease of swallowing or to provide a delayed release of active ingredients, using suitable methods.
- Tablets are typically formed by compression methods, whereas capsules are formed by filling a dry admixture into a hard outer shell.
- Liquid preparations can be in the form of solutions, syrups or suspensions, and are prepared by mixing the excipients along with the anamorelin hydrochloride in a suitable liquid medium such as water or alcohol.
- Liquid preparations (e.g., solutions, suspensions and syrups) suitable for oral administration can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl hydroxy benzoates or sorbic acid).
- suspending agents e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats
- emulsifying agents e.g., lecithin or acacia
- anamorelin free base was carefully measured and dissolved in isopropyl acetate.
- Anamorelin free base was prepared according to known method (e.g., U.S. Pat. No. 6,576,648).
- a fixed volume of HCl in water containing various molar ratios (0.80, 0.95, 1.00 or 1.05) of HCl relative to the anamorelin free base was then combined with the anamorelin/isopropyl acetate solution, to form a mixture having an organic and an aqueous phase.
- the aqueous phase of the mixture was separated from the organic phase and the resulting aqueous phase was concentrated by spray drying to obtain the batches of anamorelin monohydrochloride (or a composition comprising anamorelin monohydrochloride) shown in Table 1A.
- Chloride content (%) V ⁇ N ⁇ 35.453 ⁇ 100 ⁇ 100/ ⁇ W ⁇ [ 100 ⁇ (water content (%)) ⁇ (residual solvent (%))] ⁇
- V volume at the endpoint (mL)
- anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride
- Anamorelin free base (18.8 g, 34.4 mmol) and isopropyl acetate (341.8 g) were mixed in a 1000 mL flask. The mixture was heated at 40 ⁇ 5° C. to confirm dissolution of the crystals and then cooled at 25 ⁇ 5° C. Distilled water (22.3 g) and 3.6% diluted hydrochloric acid (33.1 g, 32.7 mmol, 0.95 equivalents) were added into the flask and washed with distilled water.
- anamorelin monohydrochloride A The physical properties of anamorelin monohydrochloride A were compared to anamorelin monohydrochloride produced by a traditional comparative method (“anamorelin monohydrochloride B”) (comparative example).
- Anamorelin mono hydrochloride B in the comparative example was produced by bubbling HCl gas into isopropyl acetate to produce a 2M solution of HCl, and reacting 0.95 molar equivalents of the 2M HCl in isopropyl acetate with anamorelin free base.
- the physical properties of anamorelin monohydrochloride B are reported in Table 1B.
- the residual solvent (organic volatile impurities) concentration (specifically isopropyl acetate) of anamorelin monohydrochloride in TABLE 1B was measured using gas chromatography (GC-2010, Shimadzu Corporation) according to the conditions shown in TABLE 1C.
- anamorelin monohydrochloride (or a composition comprising anamorelin monohydrochloride) prepared by the method of present invention had desirable chloride content, reduced residual solvent and high purity when produced under a range of spray drying conditions.
- anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride prepared according to the foregoing examples was evaluated at 25° C./75% relative humidity and 40° C./75% relative humidity for one, three and six months.
- the concentrated aqueous solution of anamorelin monohydrochloride A of example 1 was concentrated by spray drying using Niro QSD-3.6 (trade mark, GEA process engineering Inc.) to afford anamorelin monohydrochloride referred to as Batch A in Tables 2A and 2B) in an amorphous state.
- the resulting amorphous product was dissolved in acetonitrile:water (1:1) and measured under the conditions reported in Table 3A. The results are presented below in Table 3B.
- RRT refers to the relative retention time of the impurity versus anamorelin.
- the purity was converted into the amount of anamorelin free base within a sample without any other organic solvent since anamorelin monohydrochloride (or composition comprising anamorelin monohydrochloride) was dissolved in the solvent to be measured by HPLC condition.
- anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride prepared according to the present invention was nearly unchanged, and high purity was maintained for six months under each set of conditions.
- M measured total impurity (%) at specific time (e.g., 3 months, 6 month and so forth)
- the long-term stability of the anamorelin monohydrochloride (or composition comprising anamorelin monohydrochloride) (from 5.3% to 6.3% chloride content) prepared according to the present invention was nearly unchanged, and high purity was maintained for three years under ambient storage conditions (25° C./60% RH).
- the long-term stability of anamorelin dihydrochloride was easy to be changed relative to the monohydrochloride.
- the content of anamorelin dihydrochloride in the composition is increased, the composition results in less stable.
- a solution of standard curve was prepared to 356 ⁇ mol/L by diluting standard substance (anamorelin free base (quantitative value: 93.90%), 86.6 mmol/L, isopropyl acetate solution) with acetonitrile.
- a sample solution was prepared according to the process that test compound (about 100 mg) added into distilled water (10.00 g), the solution was mixed for 10 minutes at 50° C. and then was placed overnight, obtained suspension was filtered by syringe with filter (0.2 ⁇ m) and the filtrate (48.93 mg) was diluted with acetonitrile (10 mL).
- a solution of standard curve and a sample solution were determined by injecting into HPLC (GULLIVER1500 HPLC system, JASCO Corporation). Since anamorelin monohydrochloride was completely dissolved in the 25% solution of anamorelin monohydrochloride (i.e., anamorelin monohydrochloride (1 g) was dissolved in distilled water (3 mL)), a solubility of anamorelin monohydrochloride was >333 mg/mL.
- the solubility of the anamorelin monohydrochloride is superior to that of anamorelin free base in distilled water, illustrating that a reduction of chloride content in anamorelin monohydrochloride (or composition comprising anamorelin monohydrochloride) can lead to decreased solubility.
- the amorphous form of the anamorelin monohydrochloride (or composition comprising anamorelin monohydrochloride) produced by spray drying was evaluated using X-Ray powder diffraction and infrared resonance under the following measurement conditions.
- the XRPD spectra and IR spectra observed are depicted in FIGS. 1 and 2 .
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/865,649 US20140018391A1 (en) | 2012-04-20 | 2013-04-18 | Methods of Producing Anamorelin Hydrochloride Having Controlled Chloride Content |
US14/539,318 US9403867B2 (en) | 2012-04-20 | 2014-11-12 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/135,147 US9872883B2 (en) | 2012-04-20 | 2016-04-21 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/135,051 US9981002B2 (en) | 2012-04-20 | 2016-04-21 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/135,107 US9956261B2 (en) | 2012-04-20 | 2016-04-21 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/963,284 US10300105B2 (en) | 2012-04-20 | 2018-04-26 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US16/383,623 US10576122B2 (en) | 2012-04-20 | 2019-04-14 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US16/751,836 US10905737B2 (en) | 2012-04-20 | 2020-01-24 | Methods of producing anamorelin hydrochloride having controlled chloride content |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261636108P | 2012-04-20 | 2012-04-20 | |
US13/865,649 US20140018391A1 (en) | 2012-04-20 | 2013-04-18 | Methods of Producing Anamorelin Hydrochloride Having Controlled Chloride Content |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/539,318 Division US9403867B2 (en) | 2012-04-20 | 2014-11-12 | Methods of producing anamorelin hydrochloride having controlled chloride content |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140018391A1 true US20140018391A1 (en) | 2014-01-16 |
Family
ID=48225135
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/865,649 Abandoned US20140018391A1 (en) | 2012-04-20 | 2013-04-18 | Methods of Producing Anamorelin Hydrochloride Having Controlled Chloride Content |
US14/539,318 Active US9403867B2 (en) | 2012-04-20 | 2014-11-12 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/135,051 Active US9981002B2 (en) | 2012-04-20 | 2016-04-21 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/135,107 Active US9956261B2 (en) | 2012-04-20 | 2016-04-21 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/135,147 Active US9872883B2 (en) | 2012-04-20 | 2016-04-21 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/963,284 Active US10300105B2 (en) | 2012-04-20 | 2018-04-26 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US16/383,623 Active US10576122B2 (en) | 2012-04-20 | 2019-04-14 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US16/751,836 Active US10905737B2 (en) | 2012-04-20 | 2020-01-24 | Methods of producing anamorelin hydrochloride having controlled chloride content |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/539,318 Active US9403867B2 (en) | 2012-04-20 | 2014-11-12 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/135,051 Active US9981002B2 (en) | 2012-04-20 | 2016-04-21 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/135,107 Active US9956261B2 (en) | 2012-04-20 | 2016-04-21 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/135,147 Active US9872883B2 (en) | 2012-04-20 | 2016-04-21 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US15/963,284 Active US10300105B2 (en) | 2012-04-20 | 2018-04-26 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US16/383,623 Active US10576122B2 (en) | 2012-04-20 | 2019-04-14 | Methods of producing anamorelin hydrochloride having controlled chloride content |
US16/751,836 Active US10905737B2 (en) | 2012-04-20 | 2020-01-24 | Methods of producing anamorelin hydrochloride having controlled chloride content |
Country Status (47)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9872883B2 (en) | 2012-04-20 | 2018-01-23 | Helsinn Healthcare Sa | Methods of producing anamorelin hydrochloride having controlled chloride content |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20186939B (en) * | 2014-09-04 | 2018-12-25 | Healthcare Sa Helsinn | Medical treatments based on anamorelin |
EP3324958B1 (en) | 2015-07-24 | 2021-07-28 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
CN108239141A (zh) * | 2016-12-23 | 2018-07-03 | 江苏先声药业有限公司 | 一种阿拉莫林的制备方法 |
EP4021419A1 (en) | 2019-08-30 | 2022-07-06 | Helsinn Healthcare SA | Methods of manufacturing anamorelin tablets having improved stability |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576648B2 (en) * | 1999-11-10 | 2003-06-10 | Novo Nordisk A/S | Compound with growth hormone releasing properties |
WO2005030698A1 (en) * | 2003-09-26 | 2005-04-07 | Ranbaxy Laboratories Limited | Process for the preparation of voglibose |
WO2010099522A1 (en) * | 2009-02-27 | 2010-09-02 | Helsinn Therapeutics (U.S.), Inc. | Enhanced migraine treatments based on ghrelin mimetics |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006016995A1 (en) | 2004-06-29 | 2006-02-16 | Sapphire Therapeutics, Inc. | Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide |
KR20090112720A (ko) * | 2007-02-13 | 2009-10-28 | 헬신 세라퓨틱스 (유.에스.) 인크. | 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법 |
JO3353B1 (ar) | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
-
2013
- 2013-04-15 JO JOP/2013/0101A patent/JO3353B1/ar active
- 2013-04-17 AR ARP130101264A patent/AR090725A1/es not_active Application Discontinuation
- 2013-04-18 MX MX2014012178A patent/MX354793B/es active IP Right Grant
- 2013-04-18 LT LTEP13719344.7T patent/LT2838892T/lt unknown
- 2013-04-18 CA CA3031652A patent/CA3031652C/en active Active
- 2013-04-18 NZ NZ700833A patent/NZ700833A/en unknown
- 2013-04-18 EP EP19155007.8A patent/EP3517532B1/en active Active
- 2013-04-18 MA MA37524A patent/MA37524B1/fr unknown
- 2013-04-18 EA EA201401151A patent/EA031581B1/ru unknown
- 2013-04-18 CN CN201910323598.0A patent/CN110041304A/zh active Pending
- 2013-04-18 DK DK13719344.7T patent/DK2838892T3/en active
- 2013-04-18 HU HUE17192651A patent/HUE050865T2/hu unknown
- 2013-04-18 KR KR1020147018116A patent/KR101972998B1/ko active IP Right Grant
- 2013-04-18 UA UAA201412382A patent/UA116207C2/uk unknown
- 2013-04-18 BR BR112014025972A patent/BR112014025972A8/pt not_active Application Discontinuation
- 2013-04-18 CN CN201910323606.1A patent/CN110041398A/zh active Pending
- 2013-04-18 MY MYPI2014703092A patent/MY170068A/en unknown
- 2013-04-18 GE GEAP201313634A patent/GEP20186902B/en unknown
- 2013-04-18 PE PE2014001624A patent/PE20150084A1/es not_active Application Discontinuation
- 2013-04-18 US US13/865,649 patent/US20140018391A1/en not_active Abandoned
- 2013-04-18 EP EP17192651.2A patent/EP3290410B1/en active Active
- 2013-04-18 SG SG10201608488RA patent/SG10201608488RA/en unknown
- 2013-04-18 CA CA2869893A patent/CA2869893C/en active Active
- 2013-04-18 ES ES13719344.7T patent/ES2658862T3/es active Active
- 2013-04-18 SI SI201331789T patent/SI3290410T1/sl unknown
- 2013-04-18 ME MEP-2018-47A patent/ME02966B/me unknown
- 2013-04-18 RS RS20180192A patent/RS56869B1/sr unknown
- 2013-04-18 PT PT191550078T patent/PT3517532T/pt unknown
- 2013-04-18 PT PT137193447T patent/PT2838892T/pt unknown
- 2013-04-18 TW TW106105466A patent/TWI677494B/zh active
- 2013-04-18 AP AP2014008013A patent/AP2014008013A0/xx unknown
- 2013-04-18 MD MDA20140122A patent/MD4615C1/ro active IP Right Grant
- 2013-04-18 PL PL17192651T patent/PL3290410T3/pl unknown
- 2013-04-18 SG SG11201406478XA patent/SG11201406478XA/en unknown
- 2013-04-18 HU HUE13719344A patent/HUE035697T2/en unknown
- 2013-04-18 TW TW102113767A patent/TWI589572B/zh active
- 2013-04-18 DK DK19155007.8T patent/DK3517532T3/da active
- 2013-04-18 CN CN201380003026.5A patent/CN103857669B/zh active Active
- 2013-04-18 AU AU2013249197A patent/AU2013249197B2/en active Active
- 2013-04-18 PL PL13719344T patent/PL2838892T3/pl unknown
- 2013-04-18 ES ES17192651T patent/ES2820354T3/es active Active
- 2013-04-18 KR KR1020197011485A patent/KR102141323B1/ko active IP Right Grant
- 2013-04-18 EP EP13719344.7A patent/EP2838892B1/en active Active
- 2013-04-18 JP JP2015507175A patent/JP6109925B2/ja active Active
- 2013-04-18 SI SI201330963T patent/SI2838892T1/en unknown
- 2013-04-18 WO PCT/US2013/037159 patent/WO2013158874A1/en active Application Filing
- 2013-04-19 UY UY0001034753A patent/UY34753A/es active IP Right Grant
- 2013-07-29 NO NO13823572A patent/NO2877697T3/no unknown
-
2014
- 2014-10-07 IL IL235064A patent/IL235064B/en active IP Right Grant
- 2014-10-08 TN TN2014000421A patent/TN2014000421A1/fr unknown
- 2014-10-20 CL CL2014002817A patent/CL2014002817A1/es unknown
- 2014-10-20 PH PH12014502351A patent/PH12014502351A1/en unknown
- 2014-10-20 NI NI201400124A patent/NI201400124A/es unknown
- 2014-10-20 DO DO2014000235A patent/DOP2014000235A/es unknown
- 2014-11-12 US US14/539,318 patent/US9403867B2/en active Active
- 2014-11-18 EC ECIEPI201427739A patent/ECSP14027739A/es unknown
- 2014-11-19 CR CR20140530A patent/CR20140530A/es unknown
- 2014-11-19 ZA ZA2014/08508A patent/ZA201408508B/en unknown
- 2014-11-20 CO CO14255094A patent/CO7131356A2/es unknown
-
2015
- 2015-04-02 HK HK15103359.2A patent/HK1202863A1/xx unknown
-
2016
- 2016-04-21 US US15/135,051 patent/US9981002B2/en active Active
- 2016-04-21 US US15/135,107 patent/US9956261B2/en active Active
- 2016-04-21 US US15/135,147 patent/US9872883B2/en active Active
-
2017
- 2017-03-08 JP JP2017043785A patent/JP6284665B2/ja active Active
-
2018
- 2018-01-30 JP JP2018013782A patent/JP6616853B2/ja active Active
- 2018-02-21 HR HRP20180316TT patent/HRP20180316T1/hr unknown
- 2018-03-05 CY CY20181100270T patent/CY1120276T1/el unknown
- 2018-04-26 US US15/963,284 patent/US10300105B2/en active Active
- 2018-06-28 HK HK18108293.7A patent/HK1248694A1/zh unknown
-
2019
- 2019-04-14 US US16/383,623 patent/US10576122B2/en active Active
-
2020
- 2020-01-24 US US16/751,836 patent/US10905737B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576648B2 (en) * | 1999-11-10 | 2003-06-10 | Novo Nordisk A/S | Compound with growth hormone releasing properties |
WO2005030698A1 (en) * | 2003-09-26 | 2005-04-07 | Ranbaxy Laboratories Limited | Process for the preparation of voglibose |
WO2010099522A1 (en) * | 2009-02-27 | 2010-09-02 | Helsinn Therapeutics (U.S.), Inc. | Enhanced migraine treatments based on ghrelin mimetics |
US8673947B2 (en) * | 2009-02-27 | 2014-03-18 | Helsinn Therapeutics (U.S.), Inc. | Enhanced migraine treatments based on ghrelin mimetics |
Non-Patent Citations (8)
Title |
---|
Anamorelin HCl, MCE, p.1 (2016) * |
Berge et al. "Pharmaceutical salts" J. Phar. Sci 66(1) 1-19 (1977) * |
ONO-pharmaceutical Co. p.1-3 (2011) * |
Polvino "Enhanced migrain....." CA153:351081 (2010) * |
Polvino "Enhanced migraine......" CA153:351081 (2010) * |
Rousseau "Handbook of......" p.762-763 (1987) * |
Spray drying "European conference" p. 1-6 (2007) * |
Stahl "Handbook of Pharmaceutical Salts: Properties Selection and Use" Verlag Helvetica Chimica Acta: 2002, pgs. 250-253. * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9872883B2 (en) | 2012-04-20 | 2018-01-23 | Helsinn Healthcare Sa | Methods of producing anamorelin hydrochloride having controlled chloride content |
US9956261B2 (en) | 2012-04-20 | 2018-05-01 | Helsinn Healthcare Sa | Methods of producing anamorelin hydrochloride having controlled chloride content |
US9981002B2 (en) | 2012-04-20 | 2018-05-29 | Helsinn Healthcare Sa | Methods of producing anamorelin hydrochloride having controlled chloride content |
US10300105B2 (en) | 2012-04-20 | 2019-05-28 | Ono Pharmaceutical Co., Ltd | Methods of producing anamorelin hydrochloride having controlled chloride content |
US10576122B2 (en) | 2012-04-20 | 2020-03-03 | Helsinn Healthcare Sa | Methods of producing anamorelin hydrochloride having controlled chloride content |
US10905737B2 (en) | 2012-04-20 | 2021-02-02 | Helsinn Healthcare Sa | Methods of producing anamorelin hydrochloride having controlled chloride content |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10905737B2 (en) | Methods of producing anamorelin hydrochloride having controlled chloride content | |
OA17146A (en) | Methods of producing anamorelin hydrochloride having controlled chloride content |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HELSINN HEALTHCARE SA, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUWABE, SHIN-ITSU;YANAGIMACHI, TAKEHIKO;YOSHIYAMA, HIDEYUKI;AND OTHERS;SIGNING DATES FROM 20130220 TO 20130410;REEL/FRAME:030327/0037 Owner name: ONO PHARMACEUTICAL CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUWABE, SHIN-ITSU;YANAGIMACHI, TAKEHIKO;YOSHIYAMA, HIDEYUKI;AND OTHERS;SIGNING DATES FROM 20130220 TO 20130410;REEL/FRAME:030327/0037 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |